Date of Award

11-2020

Document Type

Dissertation

Degree Name

Doctor of Philosophy (PhD)

Program

Pharmaceutical Sciences

Track

Bioanalysis

Research Advisor

Wei Li, PhD

Committee

Duane D. Miller, PhD Tiffany N. Seagroves, PhD Murali M. Yallapu, PhD Junming Yue, PhD

Abstract

Triple negative breast cancer (TNBC) has aggressive clinical features strongly associated with poorer overall prognosis and higher mortality rates relative to other molecular subtypes. FDA-approved drugs, such as paclitaxel, are effective in treating TNBC. Yet, treatment failure is commonly observed due to the development of acquired chemoresistance, which remains a clinical challenge for TNBC therapy.

Declaration of Authorship

Declaration of Authorship is included in the supplemental files.

ORCID

https://orcid.org/0000-0003-4646-5885

DOI

10.21007/etd.cghs.2020.0524

2020-034-Deng-DOA.pdf (165 kB)
Declaration of Authorship

Available for download on Tuesday, November 29, 2022

Share

COinS